EP3197911A4 - Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 - Google Patents
Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 Download PDFInfo
- Publication number
- EP3197911A4 EP3197911A4 EP15844248.3A EP15844248A EP3197911A4 EP 3197911 A4 EP3197911 A4 EP 3197911A4 EP 15844248 A EP15844248 A EP 15844248A EP 3197911 A4 EP3197911 A4 EP 3197911A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- heterodimeric
- interleukin
- single chain
- improved therapeutic
- chain forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462053628P | 2014-09-22 | 2014-09-22 | |
US201462074875P | 2014-11-04 | 2014-11-04 | |
PCT/US2015/051246 WO2016048903A1 (en) | 2014-09-22 | 2015-09-21 | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3197911A1 EP3197911A1 (de) | 2017-08-02 |
EP3197911A4 true EP3197911A4 (de) | 2018-06-20 |
Family
ID=55581867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15844248.3A Withdrawn EP3197911A4 (de) | 2014-09-22 | 2015-09-21 | Verbesserter therapeutische kontrolle von heterodimeren und einkettigen formen von interleukin-12 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170291934A1 (de) |
EP (1) | EP3197911A4 (de) |
AU (1) | AU2015321603A1 (de) |
CA (1) | CA2962099A1 (de) |
IL (1) | IL251326A0 (de) |
SG (1) | SG11201702295UA (de) |
WO (1) | WO2016048903A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2251034T3 (pl) | 2005-12-02 | 2018-07-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów |
CA2905272A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
EA201890861A1 (ru) | 2015-11-09 | 2018-10-31 | Иммьюн Дизайн Корп. | Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения |
JP7246930B2 (ja) | 2016-05-18 | 2023-03-28 | モデルナティエックス インコーポレイテッド | インターロイキン-12(il12)をコードするポリヌクレオチドおよびその使用 |
US11421010B2 (en) | 2016-10-07 | 2022-08-23 | Board Of Regents, The University Of Texas System | T cells expressing membrane-anchored IL-12 for the treatment of cancer |
CN108147990B (zh) * | 2016-12-02 | 2023-01-24 | 上海中医药大学 | 一种膜锚定元件及其应用 |
EP3568474A1 (de) | 2017-01-10 | 2019-11-20 | Intrexon Corporation | Modulation der expression von polypeptiden über neue genschalterexpressionssysteme |
US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
JP2020517615A (ja) * | 2017-04-21 | 2020-06-18 | プレシゲン,インコーポレイテッド | 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達 |
JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
AU2018270111B2 (en) * | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
IL306102B1 (en) | 2017-06-07 | 2024-09-01 | Precigen Inc | Expression of new cell markers |
EP3638289A4 (de) | 2017-06-12 | 2021-03-24 | Obsidian Therapeutics, Inc. | Pde5-zusammensetzungen und verfahren zur immuntherapie |
EP3675892A4 (de) | 2017-07-03 | 2021-10-06 | Torque Therapeutics, Inc. | Immunstimulatorische fusionsmoleküle und verwendungen davon |
SG11202008508QA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Hepatitis b vaccines and uses of the same |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3849589A1 (de) * | 2018-09-14 | 2021-07-21 | ModernaTX, Inc. | Verfahren und zusammensetzungen zur krebsbehandlung mit mrna-therapeutika |
MA53822A (fr) | 2018-10-03 | 2021-08-11 | Xencor Inc | Protéines de fusion fc hétérodimères d'il -12 |
WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
WO2020160350A1 (en) * | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Modified il-12 t cell therapy for the treatment of cancer |
EP3983537A1 (de) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
EP4061417A4 (de) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | Vaccinia-viren und verfahren zur verwendung von vaccinia-viren |
US20230399370A1 (en) * | 2019-11-22 | 2023-12-14 | Alaunos Therapeutics, Inc. | Methods of treating glioblastoma |
MX2022012823A (es) * | 2020-04-17 | 2023-01-04 | Univ Leland Stanford Junior | Polipéptidos modificados de il-12 e il-23 y usos de los mismos. |
EP4143323A1 (de) * | 2020-04-30 | 2023-03-08 | VLP Therapeutics, Inc. | Cytokinimmuntherapie |
CA3215830A1 (en) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
AU2022369312A1 (en) | 2021-10-20 | 2024-05-02 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024149373A1 (en) * | 2023-01-12 | 2024-07-18 | Chengdu Ucello Biotechnology Co., Limited | Membrane-anchored cytokines, engineered immune cells, and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999060135A1 (en) * | 1998-05-21 | 1999-11-25 | Cancer Research Ventures Limited | Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases |
WO2015095249A1 (en) * | 2013-12-18 | 2015-06-25 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0956301A2 (de) * | 1996-10-18 | 1999-11-17 | Valentis Inc. | Il-12 genexpressions- und transfersysteme und verwendungen |
CA2402213C (en) * | 2000-03-15 | 2012-08-07 | Pohang University Of Science And Technology | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
EP1418184A1 (de) * | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Aus den p40 und p35 Untereinheiten des IL-12 und ein ScFv bestehendes rekombinantes Protein und seine Verwendung |
JP2009500021A (ja) * | 2005-06-30 | 2009-01-08 | アーケミックス コーポレイション | サイトカインのil−12ファミリーのポリヌクレオチドおよびポリペプチド |
-
2015
- 2015-09-21 EP EP15844248.3A patent/EP3197911A4/de not_active Withdrawn
- 2015-09-21 AU AU2015321603A patent/AU2015321603A1/en not_active Abandoned
- 2015-09-21 WO PCT/US2015/051246 patent/WO2016048903A1/en active Application Filing
- 2015-09-21 US US15/511,956 patent/US20170291934A1/en not_active Abandoned
- 2015-09-21 SG SG11201702295UA patent/SG11201702295UA/en unknown
- 2015-09-21 CA CA2962099A patent/CA2962099A1/en not_active Abandoned
-
2017
- 2017-03-22 IL IL251326A patent/IL251326A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999060135A1 (en) * | 1998-05-21 | 1999-11-25 | Cancer Research Ventures Limited | Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases |
WO2015095249A1 (en) * | 2013-12-18 | 2015-06-25 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
Non-Patent Citations (3)
Title |
---|
LODE H N ET AL: "GENE THERAPY WITH A SINGLE CHAIN INTERLEUKIN 12 FUSION PROTEIN INDUCES T CELL-DEPENDENT PROTECTIVE IMMUNITY IN A SYNGENEIC MODEL OF MURINE NEUROBLASTOMA", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 95, 1 March 1998 (1998-03-01), pages 2475 - 2480, XP002943730, ISSN: 0027-8424, DOI: 10.1073/PNAS.95.5.2475 * |
See also references of WO2016048903A1 * |
WEN-YU PAN ET AL: "Cancer Immunotherapy Using a Membrane-bound Interleukin-12 With B7-1 Transmembrane and Cytoplasmic Domains", MOLECULAR THERAPY, vol. 20, no. 5, 1 May 2012 (2012-05-01), US, pages 927 - 937, XP055327744, ISSN: 1525-0016, DOI: 10.1038/mt.2012.10 * |
Also Published As
Publication number | Publication date |
---|---|
CA2962099A1 (en) | 2016-03-31 |
EP3197911A1 (de) | 2017-08-02 |
US20170291934A1 (en) | 2017-10-12 |
SG11201702295UA (en) | 2017-04-27 |
WO2016048903A1 (en) | 2016-03-31 |
AU2015321603A1 (en) | 2017-04-13 |
IL251326A0 (en) | 2017-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251326A0 (en) | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 | |
HUS2400014I1 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
IL258931A (en) | Medicinal compounds and methods | |
EP3377102A4 (de) | Anti-pd-1-antikörper und deren therapeutische verwendungen | |
IL248211A0 (en) | mdm2 inhibitors and therapeutic methods using them | |
EP3245232A4 (de) | Heterodimeres cas9 und verfahren zur verwendung davon | |
EP3204360A4 (de) | Therapeutische verbindungen und verwendungen davon | |
EP3137606A4 (de) | Verfahren und modifikationen zur herstellung von ssrnai-verbindungen mit erhöhter aktivität, wirksamkeit und wirkungsdauer | |
GB201404470D0 (en) | Therapeutic methods and materials | |
HK1247091A1 (zh) | 治療抗體及其用途 | |
EP3265476A4 (de) | Protoxin-vii-varianten und verfahren zur verwendung | |
IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
EP3367913A4 (de) | Therapeutisches verfahren und vorrichtung | |
EP3113771A4 (de) | Therapeutische verwendung von ibogain und verwandten verbindungen | |
IL270011B (en) | Medicinal compounds and methods | |
EP3277304A4 (de) | Protoxin-vii-varianten und verfahren zur verwendung | |
EP3353159A4 (de) | Modifizierte zytotoxine und ihre therapeutische verwendung | |
EP3267796A4 (de) | Insektizide kombinationen von pip-72 und verfahren zur verwendung | |
EP3204003A4 (de) | Selenzucker und therapeutische verwendungen davon | |
AU2017901457A0 (en) | Therapeutic compounds and methods | |
AU2017901380A0 (en) | Therapeutic uses and methods | |
AU2015901423A0 (en) | Therapeutic antibodies and uses thereof | |
AU2016901176A0 (en) | Personal Therapeutic Device | |
AU2015901219A0 (en) | Therapeutic compounds and uses thereof | |
AU2014901186A0 (en) | Therapeutic Agents and Uses Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20170420 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/567 20060101ALI20180207BHEP Ipc: C07K 14/54 20060101AFI20180207BHEP Ipc: C12P 21/02 20060101ALI20180207BHEP Ipc: A61K 45/00 20060101ALI20180207BHEP Ipc: G01N 33/50 20060101ALI20180207BHEP Ipc: A61K 38/00 20060101ALI20180207BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180523 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20180516BHEP Ipc: A61K 38/00 20060101ALI20180516BHEP Ipc: C07K 14/54 20060101AFI20180516BHEP Ipc: C12P 21/02 20060101ALI20180516BHEP Ipc: G01N 33/567 20060101ALI20180516BHEP Ipc: A61K 45/00 20060101ALI20180516BHEP |
|
17Q | First examination report despatched |
Effective date: 20190514 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20191121 |